IMVAQ Therapeutics is a biotechnology startup founded in 2018 in the United States that is focused on developing innovative immuno-oncologics for the treatment of metastatic cancer. Leveraging the research of its distinguished scientific founders at Memorial Sloan Kettering Cancer Center, a renowned clinical and R&D cancer hospital, IMVAQ aims to create therapeutic products that work in synergy with the patient's immune system to eradicate cancer both locally and abscopally. The company recently secured a significant $20.00M Series B investment on 31 August 2020 from Hanne Capital.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $20.00M | 1 |
|
31 Aug 2020 |
No recent news or press coverage available for IMVAQ Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
